NASDAQ · IRD
Opus Genetics, Inc.
$3.49-$0.17 (-4.52%)
Opus Genetics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.71% below the high.
Loading market information…
NASDAQ · MRNS · USD
Stock price, earnings
Quote as of Feb 10, 2025, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Marinus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.76% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Marinus Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:29 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2023 | Aug 10, 2023 | -$0.61+19.74% vs estimate | $6.08M+6.13% vs estimate |
|---|
| Q1 2023 | May 11, 2023 | -$0.67+12.99% vs estimate | $10.38M+76.53% vs estimate |
|---|
THE ANALYST VIEW
18 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.49-$0.17 (-4.52%)
Opus Genetics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.71% below the high.
$0.71+$0.02 (+2.45%)
HEXO Corp.’s quoted price sits in the lower half of its reported 52-week range, 81.49% below the high.
$0.76$0.00 (0.0%)
IsoPlexis Corporation’s quoted price sits in the lower half of its reported 52-week range, 80.17% below the high.
$2.02+$0.13 (+6.61%)
Serina Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.7% below the high.
$1.00$0.00 (0.0%)
Angion Biomedica Corp.’s quoted price sits in the lower half of its reported 52-week range, 95.1% below the high.
$0.33+$0.00 (+0.22%)
Allakos Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.9% below the high.
$6.49+$0.01 (+0.15%)
Freeline Therapeutics Holdings plc’s quoted price sits in the upper half of its reported 52-week range, 25.79% below the high.
$4.30-$0.14 (-3.15%)
AnPac Bio-Medical Science Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 64.14% below the high.
